Details of the Drug
General Information of Drug (ID: DMZW9AC)
Drug Name |
N-Acetylalanine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-Acetyl-DL-alanine; 1115-69-1; 2-acetamidopropanoic acid; Ac-DL-Ala-OH; 2-Acetylaminopropionic acid; N-ACETYLALANINE; Acetyl-DL-Alanine; DL-Alanine, N-acetyl-; N-alpha-Acetyl-DL-alanine; 2-Acetylamino-propionic acid; N-Acetyl-S-alanine; L-Alanine, N-acetyl-; KTHDTJVBEPMMGL-UHFFFAOYSA-N; N-Acetyl-DL-2-aminopropionic Acid; 2-(acetylamino)propanoic acid; n-acetylalanin; Alanine, N-acetyl-; Alanine, N-acetyl-, L-; L-Alanine, N-acetyl- (9CI); Alanine, N-acetyl-, L- (8CI); ac-dl-alanine; n-acetyl-dl-ala; N-Acetylalanine #; EINECS 214-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure |
![]() |
||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 131.13 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||